Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATRIX-2
2023-509717-36-00Phase 3Authorised
- Sponsor
- Insel Gruppe
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3 trial of clopidogrel, prasugrel, ticagrelor, apixaban, dabigatran and 3 more in Atrial fibrillation (AFib), atrial flutter (AFL) and coronary arteriosclerosis (2 arms), sponsored by Insel Gruppe. Primary endpoints: Major adverse cardiac or cerebral events and Major or clinically relevant non-major bleeding. Planned start Dec 2024; status: authorised.
02
Drugs
clopidogrelprasugrelticagrelorapixabandabigatran
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-509717-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509717-36-00.